13,049 reports of this reaction
5.4% of all SILDENAFIL CITRATE reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for SILDENAFIL CITRATE, manufactured by Viatris Specialty LLC. There are 13,049 FDA adverse event reports linking SILDENAFIL CITRATE to DYSPNOEA. This represents approximately 5.4% of all 242,442 adverse event reports for this drug.
SILDENAFIL CITRATE has an overall safety score of 85 out of 100. Patients taking SILDENAFIL CITRATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among SILDENAFIL CITRATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for SILDENAFIL CITRATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 13,049 FDA reports for SILDENAFIL CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 5.4% of all adverse event reports for SILDENAFIL CITRATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking SILDENAFIL CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.